Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display

2615 - FOCUS4-D: Results from a randomised, placebo controlled trial (RCT) of AZD8931 (an inhibitor of signalling by HER1, 2, and 3) in patients (pts) with advanced or metastatic colorectal cancer (aCRC) in tumours that are wildtype (wt) for BRAF, PIK3CA, KRAS & NRAS


08 Oct 2016


Poster Display


Richard Adams


Annals of Oncology (2016) 27 (6): 149-206. 10.1093/annonc/mdw370


R.A. Adams1, E. Brown2, L. Brown3, R. Butler4, S. Falk5, D. Fisher3, R. Kaplan3, P. Quirke6, S. Richman6, L. Samuel7, J. Seligmann8, M. Seymour9, K.K. Shiu10, H. Wasan10, R. Wilson11, T. Maughan12

Author affiliations

  • 1 Division Of Cancer And Genetics, Cardiff University and Velindre Cancer Centre, CF14 2TL - Cardiff/GB
  • 2 Oncology, Edinburgh Cancer Centre Western General Hospital, Edinburgh/GB
  • 3 Mrc Clinical Trials Unit At Ucl, Institute of Clinical Trials and Methodology-UCL, WC2B6NH - London/GB
  • 4 Genetics, Cardiff and Vale University Helath Board Trust, Cardiff/GB
  • 5 Oncology, University Hospitals Bristol NHS Trust Bristol Haematology and Oncology Centre, Bristol/GB
  • 6 Pathology, University of Leeds-Institute of Health Sciences, Leeds/GB
  • 7 Oncology, Aberdeen Royal Infirmary, Aberdeen/GB
  • 8 Medical Oncology, The Leeds Teaching Hospital NHS Trust St. James University Hospital, LS9 7TF - Leeds/GB
  • 9 Department Of Oncology, The Leeds Teaching Hospital NHS Trust St. James University Hospital, Leeds/GB
  • 10 Oncology, University College London Hospital, London/GB
  • 11 Centre For Cancer Research And Cell Biology, Queen's University Belfast, BT9 7JL - Belfast/GB
  • 12 Oncology Clinical Trials Office (octo), Oxford Cancer and Haematology Centre, Churchill Hospital, Oxford/GB


Abstract 2615


FOCUS4 is a phase II/III trial programme testing targeted agents in pts with aCRC in molecularly stratified cohorts. Her 1,2,3 signal inhibition has been hypothesized as a mechanism for tumour control in aCRC potentially sensitive to EGFR inhibition which might delay emergence of resistance in pts responding to standard therapy.


The FOCUS4-D molecular cohort includes pts whose tumour biomarker assessment confirms wt status for BRAF, PIK3CA, KRAS & NRAS. Following 16 weeks of first-line therapy, patients with stable or responding tumours were randomised to receive either oral AZD8931 or matching lacebo. Patients were followed for progression-free-survival (PFS) as the primary outcome according to RECIST v1.1 criteria. Secondary outcomes included toxicity. Pre-planned interim analyses were agreed using Multi-Arm Multi-Stage (MAMS) trial design methodology triggered by occurrence of PFS events in the placebo arm. Cox regression was used to estimate PFS hazard ratios of AZD8931 relative to placebo adjusted for minimisation factors.


Across 18 UK sites, 32 patients were randomised (16 into each arm) between 01/2014 and 03/2016. Patients were balanced for baseline characteristics. At the first pre-planned interim analysis, the Independent Data Monitoring Committee recommended closure of FOCUS4-D on grounds of lack of activity. At this analysis, 26 patients had experienced a PFS event (11 in the placebo arm). Analyses by both Intention-to-treat (HR = 1.31 [95% CI 0.56-3.08], p = 0.54) and per-protocol (HR = 1.42 [95% CI 0.58-3.50], p = 0.49) did not indicate any benefit for PFS. Toxicity was minimal with the most frequent relating to skin rash; graded at ≥3 in 2 patients (13%).


Despite minimal toxicity, there was no evidence to suggest any efficacy of single agent Her 1,2,3 inhibition in aCRC patients whose tumour is wt for BRAF, PIK3CA, KRAS and NRAS after induction therapy in the first-line setting.

Clinical trial identification

ISRCTN90061546 EUDRACT #: 2012-005111-12

Legal entity responsible for the study

MRC CTU at University College London




R.A. Adams: Merck Serono, Servier, Amgen, Boehringer Ingelheim consultancy fees All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings